読み込み中
NASDAQHealthcareBiotechnology
最新データ
$0.7822
−$0.0098 · -1.24%
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
前日終値
$0.7822
−$0.0098 · -1.24%
日中の時刻はETです。市場データは遅延する場合があります。
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
日中レンジ
現在 $0.7822
52週レンジ
現在 $0.7822
日中の時刻はETです。市場データは遅延する場合があります。
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
日中レンジ
現在 $0.7822
52週レンジ
現在 $0.7822
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 |
|---|---|---|---|
| 研究開発 | 125.53万 USD | 210.34万 USD | 552.89万 USD |
| 販売・一般管理 | 251.25万 USD | 191.72万 USD | 309.62万 USD |
| 営業費用 | 377.24万 USD | 402.68万 USD | 863.67万 USD |
| 受取利息 | 2.56万 USD | 14.26万 USD | 36.01万 USD |
| 支払利息 | 10.09万 USD | 5000 USD | 1万 USD |
| 減価償却費と償却費 | 12万 USD | 11.86万 USD | 12.1万 USD |
| 営業利益 | −377.24万 USD | −402.68万 USD | −863.67万 USD |
| 純利益 | −384.76万 USD | −485.54万 USD | −828.2万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2026年6月22日 | 1:10 | — | — |
発効済み 2026年6月22日
1:10
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
